Stanniocalcin 1 promotes cell proliferation via cyclin E1/cyclin‑dependent kinase 2 in human prostate carcinoma

Bai,Yao; Xiao,Yichen; Dai,Yuanqing; Chen,Xiong; Li,Dongjie; Tan,Xinji; Zhang,Xiaobo

doi:10.3892/or.2017.5501

Stanniocalcin 1 promotes cell proliferation via cyclin E1/cyclin‑dependent kinase 2 in human prostate carcinoma

Authors:
- Yao Bai
- Yichen Xiao
- Yuanqing Dai
- Xiong Chen
- Dongjie Li
- Xinji Tan
- Xiaobo Zhang
View Affiliations

Affiliations: International Medical Center, Xiang Ya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, The Medical College of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Geriatric Medicine, Xiang Ya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: March 13, 2017 https://doi.org/10.3892/or.2017.5501
Pages: 2465-2471

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Stanniocalcin 1 (STC1) is a glycoprotein hormone that is involved in calcium/phosphate homeostasis. Increasing evidence suggests that STC1 is involved in carcinogenesis; however, few studies have defined the mechanisms and functional roles of STC1 activity in prostate carcinogenesis. In the present study, MTT, flow cytometry and colony formation assays, and small interfering RNA (siRNA) and overexpression in multiple cell lines were used to investigate the function of STC1 in prostate carcinoma in vivo and in vivo. Knockdown of endogenous STC1 using a siRNA decreased the proliferation of DU145 and LNCaP2 cells. These results were consistent with the changes in the protein levels of cyclin E1 and cyclin‑dependent kinase 2. By contrast, increased expression of STC1 in RWPE-1 cells led to increased cell proliferation, suggesting that STC1 promotes prostate carcinoma cell proliferation. In summary, the present study investigated the impact of STC1 on the proliferation and growth of prostate cancer in an effort to evaluate STC1 as a predictive biomarker and as a potential target for therapy.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin. 62:283–298. 2012. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Fedewa SA, Miller KD, Goding-Sauer A, Pinheiro PS, Martinez-Tyson D and Jemal A: Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin. 65:457–480. 2015. View Article : Google Scholar : PubMed/NCBI
3	Hoyne G, Rudnicka C, Sang QX, Roycik M, Howarth S, Leedman P, Schlaich M, Candy P and Matthews V: Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer. BMC Cancer. 16:1512016. View Article : Google Scholar : PubMed/NCBI
4	Marzec J, Mao X, Li M, Wang M, Feng N, Gou X, Wang G, Sun Z, Xu J, Xu H, et al: A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population. Oncotarget. 7:21393–21403. 2016.PubMed/NCBI
5	Zhou C, Dai X, Chen Y, Shen Y, Lei S, Xiao T, Bartfai T, Ding J and Wang MW: G protein-coupled receptor GPR160 is associated with apoptosis and cell cycle arrest of prostate cancer cells. Oncotarget. 7:12823–12839. 2016.PubMed/NCBI
6	Orr B, Riddick AC, Stewart GD, Anderson RA, Franco OE, Hayward SW and Thomson AA: Identification of stromally expressed molecules in the prostate by tag-profiling of cancer-associated fibroblasts, normal fibroblasts and fetal prostate. Oncogene. 31:1130–1142. 2012. View Article : Google Scholar : PubMed/NCBI
7	Ono M, Ohkouchi S, Kanehira M, Tode N, Kobayashi M, Ebina M, Nukiwa T, Irokawa T, Ogawa H, Akaike T, et al: Mesenchymal stem cells correct inappropriate epithelial-mesenchyme relation in pulmonary fibrosis using stanniocalcin-1. Mol Ther. 23:549–560. 2015. View Article : Google Scholar : PubMed/NCBI
8	Ohkouchi S, Ono M, Kobayashi M, Hirano T, Tojo Y, Hisata S, Ichinose M, Irokawa T, Ogawa H and Kurosawa H: Myriad functions of stanniocalcin-1 (STC1) cover multiple therapeutic targets in the complicated pathogenesis of idiopathic pulmonary fibrosis (IPF). Clin Med Insights Circ Respir Pulm Med. 9:(Suppl 1). S91–S96. 2015.
9	Lee S, Naesens M, Li L and Sarwal M: Stanniocalcin supports the functional adaptation of adult-sized kidneys transplanted into the pediatric recipients. Transplantation. 93:1130–1135. 2012. View Article : Google Scholar : PubMed/NCBI
10	Tang SE, Wu CP, Wu SY, Peng CK, Perng WC, Kang BH, Chu SJ and Huang KL: Stanniocalcin-1 ameliorates lipopolysaccharide-induced pulmonary oxidative stress, inflammation, and apoptosis in mice. Free Radic Biol Med. 71:321–331. 2014. View Article : Google Scholar : PubMed/NCBI
11	Law AY and Wong CK: Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp Cell Res. 316:466–476. 2010. View Article : Google Scholar : PubMed/NCBI
12	Li Y, Yang XH, Fang SJ, Qin CF, Sun RL, Liu ZY, Jiang BY, Wu X and Li G: HOXA7 stimulates human hepatocellular carcinoma proliferation through cyclin E1/CDK2. Oncol Rep. 33:990–996. 2015.PubMed/NCBI
13	Peña C, Céspedes MV, Lindh MB, Kiflemariam S, Mezheyeuski A, Edqvist PH, Hägglöf C, Birgisson H, Bojmar L, Jirström K, et al: STC1 expression by cancer-associated fibroblasts drives metastasis of colorectal cancer. Cancer Res. 73:1287–1297. 2013. View Article : Google Scholar : PubMed/NCBI
14	Ma X, Gu L, Li H, Gao Y, Li X, Shen D, Gong H, Li S, Niu S, Zhang Y, et al: Hypoxia-induced overexpression of stanniocalcin-1 is associated with the metastasis of early stage clear cell renal cell carcinoma. J Transl Med. 13:562015. View Article : Google Scholar : PubMed/NCBI
15	Zhou H, Li YY, Zhang WQ, Lin D, Zhang WM and Dong WD: Expression of stanniocalcin-1 and stanniocalcin-2 in laryngeal squamous cell carcinoma and correlations with clinical and pathological parameters. PLoS One. 9:e954662014. View Article : Google Scholar : PubMed/NCBI
16	Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH and Liu J: Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst. 102:812–827. 2010. View Article : Google Scholar : PubMed/NCBI
17	Du YZ, Gu XH, Li L and Gao F: The diagnostic value of circulating stanniocalcin-1 mRNA in non-small cell lung cancer. J Surg Oncol. 104:836–840. 2011. View Article : Google Scholar : PubMed/NCBI
18	Chang AC, Doherty J, Huschtscha LI, Redvers R, Restall C, Reddel RR and Anderson RL: STC1 expression is associated with tumor growth and metastasis in breast cancer. Clin Exp Metastasis. 32:15–27. 2015. View Article : Google Scholar : PubMed/NCBI
19	Park WY, Hong BJ, Lee J, Choi C and Kim MY: H3K27 demethylase JMJD3 employs the NF-κB and BMP signaling pathways to modulate the tumor microenvironment and promote melanoma progression and metastasis. Cancer Res. 76:161–170. 2016. View Article : Google Scholar : PubMed/NCBI
20	Gu J, Law AY, Yeung BH and Wong CK: Activation of gill Ca²⁺-sensing receptor as a protective pathway to reduce Ca²⁺-induced cytotoxicity. J Mol Endocrinol. 53:155–164. 2014. View Article : Google Scholar : PubMed/NCBI
21	Shi X, Wang J and Qin Y: Recombinant adeno-associated virus-delivered hypoxia-inducible stanniocalcin-1 expression effectively inhibits hypoxia-induced cell apoptosis in cardiomyocytes. J Cardiovasc Pharmacol. 64:522–529. 2014. View Article : Google Scholar : PubMed/NCBI
22	Nagappan A, Lee HJ, Saralamma VV, Park HS, Hong GE, Yumnam S, Raha S, Charles SN, Shin SC, Kim EH, et al: Flavonoids isolated from Citrus platymamma induced G2/M cell cycle arrest and apoptosis in A549 human lung cancer cells. Oncol Lett. 12:1394–1402. 2016.PubMed/NCBI
23	Huang Y, Zhao S, Zhang Y, Zhang C and Li X: Downregulation of coding transmembrane protein 35 gene inhibits cell proliferation, migration and cell cycle arrest in osteosarcoma cells. Exp Ther Med. 12:581–588. 2016.PubMed/NCBI
24	Tsai TC, Huang HP, Chang KT, Wang CJ and Chang YC: Anthocyanins from roselle extract arrest cell cycle G2/M phase transition via ATM/Chk pathway in p53-deficient leukemia HL-60 cells. Environ Toxicol. Jul 22–2016.(Epub ahead of print). doi: 10.1002/tox.22324.
25	Huang MY, Xuan F, Liu W and Cui HJ: MINA controls proliferation and tumorigenesis of glioblastoma by epigenetically regulating cyclins and CDKs via H3K9me3 demethylation. Oncogene. Jun 13–2016.(Epub ahead of print). doi: 10.1038/onc.2016.208.
26	Hydbring P, Malumbres M and Sicinski P: Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat Rev Mol Cell Biol. 17:280–292. 2016. View Article : Google Scholar : PubMed/NCBI
27	de Azevedo WF: Opinion paper: Targeting multiple cyclin-dependent kinases (CDKs): A new strategy for molecular docking studies. Curr Drug Targets. 17:22016. View Article : Google Scholar : PubMed/NCBI
28	Liu QX, Wang XF, Ikeo K, Hirose S, Gehring WJ and Gojobori T: Evolutionarily conserved transcription factor Apontic controls the G1/S progression by inducing cyclin E during eye development. Proc Natl Acad Sci USA. 111:9497–9502. 2014. View Article : Google Scholar : PubMed/NCBI
29	Gladden AB and Diehl JA: Cell cycle progression without cyclin E/CDK2: Breaking down the walls of dogma. Cancer Cell. 4:160–162. 2003. View Article : Google Scholar : PubMed/NCBI
30	Rath SL and Senapati S: Why are the truncated cyclin Es more effective CDK2 activators than the full-length isoforms? Biochemistry. 53:4612–4624. 2014. View Article : Google Scholar : PubMed/NCBI